High Frequency Oscillatory Ventilation Versus High Frequency Jet Ventilation for Congenital Diaphragmatic Hernia
Launched by UNIVERSITY OF UTAH · Feb 24, 2021
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different types of breathing support for newborns with a condition called congenital diaphragmatic hernia (CDH), which affects how their lungs develop. The goal is to find out which method—high frequency jet ventilation (HFJV) or high frequency oscillatory ventilation (HFOV)—helps these babies breathe better after birth. In this trial, babies admitted to the University of Utah or Primary Children's Hospital within 24 hours of birth and who need help breathing will be randomly assigned to receive either HFJV or HFOV.
To be eligible for the trial, babies must be less than 24 hours old, require mechanical ventilation, and have an arterial line in place for monitoring. The study will compare how well the two ventilation methods work in terms of oxygen and overall blood flow. Parents can expect to give consent for their baby's participation, and this research is important in improving care for infants with CDH. The trial is currently recruiting participants, and all eligible babies can take part, regardless of gender.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Admitted to either the University of Utah and/or Primary Children's Hospital NICU within 24 hours of birth
- • 2. Requiring mechanical ventilation
- • 3. Umbilical arterial line or peripheral arterial line in place
- • 4. Obtained signed consent
- • 5. Infant is ≤ 24 hours of age
- Exclusion Criteria:
- • 1. Severe anomaly
- • 1. Chromosomal abnormalities
- • 2. Major congenital anomalies, including cardiac, central nervous system and syndromes
- • 2. Post-natal diagnosis \> 24 hours of life
- • 3. Unable to obtain consent for participation
- • 4. Unable to randomize within 24 hours of life
About University Of Utah
The University of Utah is a prestigious research institution known for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust infrastructure that supports a wide range of biomedical research initiatives, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies. By fostering collaboration among researchers, clinicians, and community partners, the University of Utah aims to translate scientific discoveries into effective therapies and interventions, ultimately enhancing health outcomes and contributing to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salt Lake City, Utah, United States
Salt Lake City, Utah, United States
Patients applied
Trial Officials
Michelle Yang, MD
Principal Investigator
University of Utah
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials